Cencora Appoints Eva Boratto as Executive VP and CFO
COR is trading near its 52-week low of $244.82 (10% above the low).
Summary
Cencora announced the appointment of Eva Boratto, a former CFO of Bath & Body Works and CVS Health, as its new Executive Vice President and Chief Financial Officer, while also reaffirming its fiscal 2026 and long-term financial guidance.
Key Events · Executive and Board Changes · COR
-
New CFO Appointed
Eva C. Boratto, with extensive experience including CFO roles at Bath & Body Works and CVS Health, has been appointed Executive Vice President and Chief Financial Officer, effective June 29, 2026.
-
Succession Plan Finalized
Ms. Boratto succeeds James F. Cleary, whose retirement was previously announced on March 17, 2026. Mr. Cleary will serve in an advisory capacity through the end of 2026 to ensure a smooth transition.
-
Compensation Package Detailed
Ms. Boratto will receive an annual base salary of $1,000,000, a $2,000,000 cash sign-on bonus, and a $6,000,000 restricted stock unit award vesting over three years.
-
Guidance Reaffirmed
Cencora reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.70 to $17.90 and its long-term guidance for adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%. This guidance was recently updated on May 21, 2026.
Analysis · COR · Trade & Services
Cencora has appointed Eva Boratto, a seasoned executive with prior CFO experience at Bath & Body Works and CVS Health, as its new Executive Vice President and Chief Financial Officer. This appointment resolves the previously announced retirement of James F. Cleary and brings a highly experienced financial leader to the company. The company also reaffirmed its recently updated fiscal year 2026 and long-term financial guidance, signaling stability in its outlook.
At the time of this filing, COR was trading at $269.36 on NYSE in the Trade & Services sector, with a market capitalization of approximately $52.4B. The 52-week trading range was $244.82 to $377.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.